Evoxac

   
Google
 
Web NewDrugInformation.com

Evoxac


Drug - Evoxac
The trade name of the product as shown on the labeling.

Dosage - CAPSULE; ORAL
The product dosage form and route separated by a semi-colon.

Active Ingredient(s) - Cevimeline Hydrochloride
Multiple ingredients are in alphabetical order.

Strength - EQ 30MG BASE
The potency of the active ingredient(s), Cevimeline Hydrochloride. May repeat for multiple part products.

Applicant - DAIICHI
The firm name holding legal responsibility for Evoxac. The firm name is condensed to a maximum twenty character unique string.

New Drug Application (NDA) Number - 020989
The FDA assigned number to Evoxac. Format is nnnnnn.

Product Number - 002
The FDA assigned number to identify Evoxac. Each strength is a separate product. May repeat for multiple part products. Format is nnn.

Therapeutic Equivalence (TE) Code -
The TE Code indicates the therapeutic equivalence rating of generic to innovator Rx products.

Approval Date - Jan 11, 2000
The date Evoxac was approved as stated in the FDA approval letter to the applicant. The format is Mmm dd, yyyy. Products approved prior to the January 1, 1982 contain the phrase: "Approved prior to Jan 1, 1982".

Reference Listed Drug (RLD) - Yes
The pioneer or innovator of Evoxac. The RLD identifies the product Abbreviated New Drug Applications (ANDA) use as a reference. Format is Yes or No.

Type - RX
The group or category of approved drugs Evoxac is in. Format is RX, OTC, DISCN.

Applicant Full Name - Daiichi Medical Research Inc
The full name of the firm holding legal responsibility for the new application of Evoxac.

Evoxac